Alps Group Inc(ALPS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.18
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ALPS

11/13/2026: ALPS (1-star) is currently NOT-A-BUY. Pass it for now.

Alps Group Inc is a micro-cap biotechnology and healthcare company headquartered in Malaysia that integrates advanced molecular research, genomics, and clinical wellness services. The company's primary business strengths lie in its accredited MyGenome whole genome sequencing capabilities and expanding suite of precision medicine solutions. Its core growth story centers on capitalizing on rising regional demand for preventive healthcare and precision oncology. However, the company faces notable risks, including persistent net losses, micro-cap share volatility, and intense competition from established global diagnostics firms. The stock may best suit speculative or momentum-oriented investors willing to monitor clinical execution and cash burn developments closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers exposure to expanding biotech and genomics markets, but its micro-cap scale introduces execution uncertainties.
Momentum investorStrong fit while signal remains positiveLow-float micro-cap biotech shares can experience sharp momentum-driven price movements when positive clinical news occurs.
Value investorWeak fitThe lack of consistent net profitability and negative earnings make it unsuitable for traditional value investing metrics.
Dividend investorWeak fitThe company pays no dividends and retains all capital to fund research and business operations.
Low-risk investorWeak fitHigh share price volatility and micro-cap status expose investors to significant downside risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock exhibits high historical price swings and sensitivity typical of micro-cap equities.
Valuation riskMedium / highNegative earnings and early-stage revenues complicate traditional fundamental valuation.
Competition risk (diagnostics and genomics competition)HighThe company competes with well-funded global diagnostics and biotechnology giants.
Business qualityMediumIntegrated operations and certified labs provide a sound foundation, but overall scale is modest.
Dividend incomeLow / noneNo dividend distributions are offered to shareholders.
Execution riskHighSuccess depends heavily on commercializing new genomic tests and scaling clinical facilities profitably.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 37.38M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 18.4K shares
Beta -
52 Weeks Range 1.01 - 8.60
Updated Date 11/15/2026
52 Weeks Range 1.01 - 8.60
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -

Sector & Industry Intelligence

Sector intelligence is unavailable for this snapshot.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ALPS receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
ALPS has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and soft ownership. Growth and ownership metrics are mixed: slightly negative earnings growth (+0.0%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
ALPS's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
ALPS's growth profile is soft, with the least-weak measure being revenue growth at +0.0% year over year. By comparison, while earnings growth (+0.0%, slightly negative) and free-cash-flow growth (+0.0%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 0.0% (soft) and 0.0% of outstanding shares are publicly tradable (soft). Insider ownership is only 0.00%, which materially reduces the ownership score.

Top 5 Institutional Investors

Millennium Management LLC 0.22%
Mmcap International Inc. Spc 0.03%
Citadel Advisors Llc 0.03%
JONES FINANCIAL COMPANIES LLLP 0.02%
Susquehanna International Group, LLP 0.01%

Unit Economics (Per $1K Revenue)

★★★★★
ALPS generates approximately $0 of gross profit, $0 of operating income, and $0 of free cash flow for every $1,000 of revenue. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 21.00%

Quantitative Style Profile

★★★★★
ALPS has a relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Medical and Wellness ServicesNon-surgical and surgical aesthetic treatments, medical consultations, health screenings, and cellular therapy.This segment provides the core near-term clinical and wellness service revenues.
Life Science and GenomicsWhole-genome sequencing, pharmacogenomics, and patient-derived organoid testing.This segment drives the higher-margin scientific research and advanced diagnostics potential.
Geographic Exposure (Malaysia)Clinical laboratories, medical centers, and wellness hubs primarily anchored in Malaysia.Operations are currently regional, concentrating execution exposure in Southeast Asia.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 37.33M
Price to Sales(TTM) 8.09
Enterprise Value 37.33M
Price to Sales(TTM) 8.09
Enterprise Value to Revenue 7.69
Enterprise Value to EBITDA -
Shares Outstanding 3.00M
Shares Floating -
Shares Outstanding 3.00M
Shares Floating -
Percent Insiders -
Percent Institutions -

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.